At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Nov 2, 2026 at 16:05 ET
Bioventus reported Q3 2026 non-GAAP EPS of $0.17, beating the $0.16 consensus by 6.3%, while revenue of $142.4M missed the $149.5M consensus by 4.7%. The company reaffirmed its full-year adjusted EPS guidance of $0.75-$0.79 but narrowed net sales guidance to $590M-$595M, implying 4-5% growth. The ongoing review of strategic alternatives adds an M&A overhang.
- Non-GAAP EPS of $0.17 beat consensus of $0.16 by 6.3%
- Revenue of $142.4M missed consensus of $149.5M by 4.7%
- Revenue grew 2.7% YoY, below the 5% bullish threshold
- Pain Treatments revenue grew 6.2% YoY to $71.3M
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access